Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Public ClinicalTrials.gov record NCT05890729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
Study identification
- NCT ID
- NCT05890729
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2023 (Actual)
- Primary completion
- Oct 31, 2026 (Estimated)
- Completion
- Oct 31, 2026 (Estimated)
- Last update posted
- Oct 2, 2026
2023 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Xentria Investigative Site | Birmingham | Alabama | 35233 | — |
| Xentria Investigative Site | Denver | Colorado | 80206 | — |
| Xentria Investigative Site | Jacksonville | Florida | 32209 | — |
| Xentria Investigative Site | Chicago | Illinois | 60611 | — |
| Xentria Investigative Site | Chicago | Illinois | 60612 | — |
| Xentria Investigative Site | Iowa City | Iowa | 52242 | — |
| Xentria Investigative Site | Baltimore | Maryland | 21287 | — |
| Xentria Investigative Site | Detroit | Michigan | 48202 | — |
| Xentria Investigative Site | Minneapolis | Minnesota | 55455 | — |
| Xentria Investigative Site | Albany | New York | 12208 | — |
| Xentria Investigative Site | New York | New York | 10029 | — |
| Xentria Investigative Site | Greenville | North Carolina | 27858 | — |
| Xentria Investigative Site | Cincinnati | Ohio | 45267 | — |
| Xentria Investigative Site | Philadelphia | Pennsylvania | 19140 | — |
| Xentria Investigative Site | Charleston | South Carolina | 29425 | — |
| Xentria Investigative Site | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05890729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2026 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05890729 live on ClinicalTrials.gov.